Department of Pharmacology, School of Medicine, Tzu Chi University, Hualien 970, Taiwan.
Master Program in Medical Physiology, School of Medicine, Tzu Chi University, Hualien 970, Taiwan.
Biomolecules. 2020 Jan 16;10(1):149. doi: 10.3390/biom10010149.
Acute hypertension produced by methamphetamine (MA) is well known, mainly by the enhancement of catecholamine release from sympathetic terminals. However, the central pressor mechanism of the blood-brain-barrier-penetrating molecule remains unclear. We used radio-telemetry and femoral artery cannulation to monitor the mean arterial pressure (MAP) in conscious free-moving and urethane-anesthetized rats, respectively. Expression of Fos protein (Fos) and phosphorylation of N-methyl-D-aspartate receptor subunit GluN1 in the rostral ventrolateral medulla (RVLM) were detected using Western blot analysis. ELISA was carried out for detection of protein kinase C (PKC) activity in the RVLM. MA-induced glutamate release in the RVLM was assayed using in vivo microdialysis and HPLC. Systemic or intracerebroventricular (i.c.v.) administration of MA augments the MAP and increases Fos expression, PKC activity, and phosphorylated GluN1-ser 896 (pGluN1-ser 896) in the RVLM. However, direct microinjection of MA into the RVLM did not change the MAP. Unilateral microinjection of a PKC inhibitor or a metabotropic glutamate receptor 5 (mGluR5) antagonist into the RVLM dose-dependently attenuated the i.c.v. MA-induced increase in MAP and pGluN1-ser 896. Our data suggested that MA may give rise to glutamate release in the RVLM further to the activation of mGluR5-PKC pathways, which would serve as a central mechanism for the MA-induced pressor effect.
甲基苯丙胺(MA)引起的急性高血压众所周知,主要是通过增强交感神经末梢儿茶酚胺的释放。然而,血脑屏障穿透分子的中枢加压机制仍不清楚。我们分别使用无线电遥测和股动脉插管监测清醒自由活动和氨基甲酸乙酯麻醉大鼠的平均动脉压(MAP)。使用 Western blot 分析检测延髓头端腹外侧区(RVLM)中的 Fos 蛋白(Fos)表达和 N-甲基-D-天冬氨酸受体亚基 GluN1 的磷酸化。通过 ELISA 检测 RVLM 中的蛋白激酶 C(PKC)活性。使用体内微透析和 HPLC 测定 RVLM 中的 MA 诱导的谷氨酸释放。MA 全身或脑室内(i.c.v.)给药可增强 MAP,并增加 RVLM 中的 Fos 表达、PKC 活性和磷酸化 GluN1-ser 896(pGluN1-ser 896)。然而,直接将 MA 微注射到 RVLM 中不会改变 MAP。将 PKC 抑制剂或代谢型谷氨酸受体 5(mGluR5)拮抗剂单侧微注射到 RVLM 中可剂量依赖性地减弱 i.c.v. MA 诱导的 MAP 和 pGluN1-ser 896 的增加。我们的数据表明,MA 可能会导致 RVLM 中的谷氨酸释放,进一步激活 mGluR5-PKC 途径,这可能是 MA 引起升压作用的中枢机制。